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Abstract
This research examines the timeline of the discovery and research of Primary Open-Angle Glaucoma (POAG).
By reviewing the literature on genetic and molecular mechanisms, we aim to emphasize a long-term treatment
solution (iSTENT) to mitigate intraocular pressure (IOP) related to POAG etiology and disease progression.
POAG is a multifactorial, autosomal dominant, adult-onset eye disease wherein the optic nerve cells become
damaged due to a buildup of excess aqueous humor, resulting in increased IOP. Consequently, POAG leads to
progressive loss of peripheral vision and is the leading cause of blindness in the US. Due to the multifactorial
nature of glaucoma’s inheritance pattern and disease pathology, over 20 disease-associated loci have been
implicated with POAG and its mechanisms remain relatively obscure. POAG remains a hotbed for
multifactorial genetic research and the relationships between heterogeneity and environmental/genetic factors.
To develop a more permanent solution for Glaucoma, we highlight a surgical insertion of a stent in the
trabecular meshwork providing long-lasting dilation to the blocked drainage channels implicated with increased
IOP and POAG progression. This procedure would allow for aqueous humor outflow from the eye and
subsequent reduction of pressure-induced retinal ganglion cell damage. POAG’s progressive loss of vision due
to polygenic inheritance and environmental factors is currently experienced by over 2.25 million Americans and
will continue to grow as POAG-associated genes are maintained in subsequent generations. Therefore, a
complete understanding of the history, etiology, and genetic mechanisms is critical for the development of
effective and long-lasting treatment options.
Keywords: genetics, multifactorial disease, MYOC (gene), intraocular pressure (IOP), blindness, iSent Medical
Device
In a healthy eye, fluid called aqueous humor is
secreted into the posterior chamber (behind the iris) via
the ciliary processes attached to the ciliary body. The
aqueous humor then crosses the pupil to provide
nutrients to the cornea (clear portion) in the anterior
chamber (in front of the iris) of the eye (Llobet et al.,
2003). Lastly, the eye fluid exits the anterior chamber
through the trabecular meshwork tissue (TM) and

subsequently through Schlemm’s canal (See Figure 1
for anatomy of the eye).
In contrast, Primary Open-Angle Glaucoma
(POAG) is an adult-onset eye disease that causes
progressive blindness, typically beginning with a
gradual loss of peripheral vision. This disease is often
a result of defects in the trabecular meshwork
preventing aqueous humor from properly exiting the
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eye cavity through drainage channels. This inability of
the aqueous humor to drain properly causes a build-up
in intraocular pressure (IOP), referring to fluid pressure
within the eye. As IOP increases due to blocked or
collapsed drainage channels in the trabecular
meshwork, retinal ganglion cells (optic nerve cells)
become severely damaged or undergo apoptosis (cell
death) resulting in the permanent progressive loss of
vision (See Figure 2 for an illustration of the
development of glaucoma). The “Open-Angle” portion
of the POAG name refers to the presence of space
between the iris and cornea.
From a genetic perspective, POAG is a
multifactorial disease with complex inheritance
meaning that multiple genes have been known to cause
or affect the expression of the disease. Additionally,
the penetrance and expressivity of POAG can vary
drastically from patient to patient (Gemenetzi et al.,
2012). In other words, people who carry the POAG
mutations may or may not exhibit signs and symptoms
of the disease. Genetic and environmental modifiers of
POAG interact to contribute to the notable complexity
of its disease etiology, severity, and inheritance
patterns. Some of the most common non-genetic
modifiers include race, untreated high blood pressure,
cigarette smoking, family history of glaucoma,
diabetes, and being nearsighted. Currently, there is no
permanent cure for POAG and current treatment
options require daily use of specialized IOP reducing
eye drops or multiple follow-up procedures. Thus,
using current and historical research, we investigate a
molecular mechanism of POAG to emphasize a
permanent treatment solution to IOP-induced retinal
ganglion cell injury/death using an in-development
medical device known as the iStent.
Literature Review
Early History:
400 BCE Hippocrates
Taking a look at the history, Glaucoma has
been prevalent in the human population dating back to
400BCE where it was mentioned by Hippocrates, the
Father of Modern Medicine. He referred to this
condition as “Glaykoseis” - blindness that occurs in
the elderly (Leffler, 2015).
502-575 CE Aetius of Amida
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By 500CE a Byzantine physician, Amida,
grouped it under the term “Amaurosis”, a
categorization used to describe eye diseases that caused
severe vision impairment as a result of increased eye
pressure on the optic nerve in patients with eyes that
appeared normal (Leffler, 2015).
1101-1300 Benevenutus Grassus
12th-century optometrist Benevenutus Grassus
coined the term “gutta serena” to describe incurable
blindness caused by an obstructed optic nerve (Leffler,
2015).
1850 Invention of Ophthalmoscope
In the 1850s a breakthrough in diagnosis
occurred with the invention of the ophthalmoscope.
For the first time in history, this revolutionary device
allowed physicians to visually identify a degraded
optic nerve and finally led to the inception of the
current name “Glaucoma” (Leffler, 2015).
1856 Albrecht von Graefe
Albrecht von Graefe introduced iridectomy as
one of the earliest forms of glaucoma treatment. This
operation involves surgical removal of a segment of the
iris allowing for drainage of excess fluid from the eye.
Graefe then went on to invent the tonometer, a tool
currently used to measure the eye pressure of glaucoma
patients. Graefe is also credited with the
implementation of visual field testing, a commonly
used practice used to identify and diagnose glaucoma
(Leffler, 2015).
1960 Trabeculectomy Introduced
In 1960 Trabeculectomy, a procedure that
involves surgical removal of a small portion of the
trabecular meshwork to drain aqueous humor was
introduced. This procedure shifted several future
procedures towards the trabecular meshwork and its
drainage channels as a new, more efficient target for
surgical intervention (Razeghinejad, 2011).
1967 Discovery of Multifactorial Disease Etiology
The study by Mansour, F. P., described
POAG’s locus heterogeneity by performing parentoffspring transmission comparisons (i.e. pedigree).
This study further concluded polygenic inheritance in
POAG, with variable age of onset and expressivity.
This discovery confirmed that multiple genes along
with environmental factors all played a collective role
in disease manifestation and severity (Armaly, 2017).
1996 Prostaglandin Medications Introduced
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First eye drops that reduce intraocular pressure
are introduced and are still currently the first line of
medical therapy for glaucoma. Prostaglandins act by
activating receptors that can trigger a restructuring of
the extracellular matrix to allow for aqueous outflow
(Fingeret, 2001).
1997 Discovery of First Disease-Associated Gene
MYOC
A study by Stone et al performed SequenceTagged Sites (STS) on candidate genes based on
affected familial association studies of POAG.
Radiation hybrid gene mapping was used to suggest the
presence of the MYOC disease-associated gene near
the candidate gene markers (Stone et al., 1997).
1997 Laser Trabeculoplasty Introduced
Laser-based surgery, in which a laser is used to
cut damaged regions of the trabecular meshwork,
begins being practiced by optometrists. This procedure
currently remains the most frequently used glaucoma
treatment (Razeghinejad, 2011).
Current Research:
2009 Identification of 3 susceptible Loci in Japanese
Populations
3 susceptible loci on chromosomes 1, 10, and
12 were identified using a genome-wide SNP
association study of 418 POAG patients. Glaucoma
was found to exhibit familial aggregation (autosomal
dominant; ~50% inheritance), with variable penetrance
& expressivity amongst individuals and various ethnic
groups (African Americans, Japanese and Northern
Europeans) (Nakano et al., 2009).
2009 Investigation of MYOC Hotspots on Glaucoma
Etiology
This 2009 research found several POAGassociated mutations are often a result of Single
Nucleotide Polymorphisms (SNPs). The MYOC gene
which encodes the protein myocilin, produced in the
trabecular meshwork tissue, was discovered to be a key
hotspot in Glaucoma etiology.
The exact function of myocilin is unknown.
However, various mutations of MYOC have been
associated with retinal ganglion damage and death.
This study indicated that the MYOC gene segment, in
particular, accrues several point mutations. These point
mutations occur most commonly as a result of
spontaneous or mutagen-induced DNA damage,

26

causing errors in DNA replication/repair by DNA
polymerase (Kwon et al., 2009).
2013 Research Implicates Dual Leucine Zipper Kinase
as a Key Mediator of Retinal Ganglion Cell Apoptosis
A 2013 Research identified several important
myocilin domains and some of their normal roles.
From the illustrations above, dual Leucine zipper
kinase in the N-terminus was discovered to be a highly
important signaling component during axonal damage
& retinal ganglion cell death, while the C-terminal
domains in myocilin functioned to direct proteins to
peroxisomes for oxidation reactions (Welsbie et al.,
2013).
2013 Research Implicates Dual Leucine Zipper Kinase
as a Key Mediator of Retinal Ganglion Cell Apoptosis
A 2013 Research identified several important
myocilin domains and some of their normal roles.
From the illustrations above, dual Leucine zipper
kinase in the N-terminus was discovered to be a highly
important signaling component during axonal damage
& retinal ganglion cell death, while the C-terminal
domains in myocilin functioned to direct proteins to
peroxisomes for oxidation reactions (Welsbie et al.,
2013).
2015 Psychosocial Study on Glaucoma-Associated
Visual Acuity & Field Loss
This study found that glaucoma-related loss of
visual acuity and field had significant psychosocial
effects on the patients. This was determined using a
quality of life questionnaire of 192 patients. Results
indicated that glaucoma patients had 63% greater
anxiety, 71% lower self-image, 38% less psychological
well-being & 32.4% reduced confidence in health care
compared to negative controls (Chan et al., 2015).
2017 Genome-wide Association Identifies 16 total
POAG-associated Gene Loci
Genome-wide association studies for different
types of adult-onset glaucoma have identified 16 total
POAG-associated loci involved in a variety of
important biological functions including; cytokine
signaling, lipid metabolism, membrane biology, and
ocular development.
This discovery truly emphasizes the complex,
multifactorial nature of this disease. Several of these
seemingly unrelated genetic loci could be acting
together or independently to reduce or exacerbate the
condition of this glaucoma. This relative abundance of
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genetic modifiers coupled with environmental factors
contributes to the notable heterogeneity of glaucoma
manifestation (multifactorial) (Bailey et al., 2016).
Potential Long-Term Treatment (iStent): Due to the
complex, multifactorial nature of glaucoma, genetic
intervention and long-term IOP reducing therapy may
present significantly challenging biological/financial
barriers (Wiggs et al., 2017). Therefore, consideration
of more permanent solutions such as the iStent or other
stent-based procedures could provide efficient
protection against progressive loss of vision and offer
additional long-term health and financial benefits.
Surgical insertion of the iStent® (stent) into the
trabecular meshwork allows aqueous humor to drain
freely into the Schlemm’s canal from the anterior
chamber, reducing IOP-induced retinal ganglion cell
damage and death (Resende et al., 2016). This
procedure is known as minimally invasive glaucoma
surgery (MIGS) has shown notably low complication
rates and long-term reduction in unmedicated IOP.
A 13-month follow-up of 39 POAG patients
treated with the insertion of 2 iStents has exhibited a
mean unmedicated IOP reduction of 25.3 ± 1.8 mmHg
preoperatively to 17.1 ± 2.2 mmHg (32.4%) (Resende
et al., 2016). Due to the notable heterogeneity of
glaucoma, it is an important model for the study of
multifactorial disease etiology.
Discussion
POAG’s incurable progressive loss of vision is
currently experienced by over 2.25 million Americans
and remains the leading cause of blindness in the US.
With a long history of prevalence in individuals dating
back to as early as 400 BCE (Leffler, 2015), this
disease possesses multifactorial characteristics
contributing to the complexity of this disease's
penetrance, expressivity, and overall inheritance
patterns.
POAG’s influence from both genetic and
environmental modifiers also diminishes the accurate
evaluation of POAG prognosis. Patients typically
exhibit varying severity of symptoms with individuals
who may even be completely unaware of their
condition due to its often gradual progression.
Furthermore, the incurable progressive blindness due
to POAG has also been shown to additionally cause a
decline in the mental state of the patients, highlighting
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several of the long-term, non-physical implications of
this disease (Zhou et al., 2016).
Current research has also identified several of
the proteinaceous, structural defects of POAGimplicated gene products such as Myocilin from the
MYOC gene. Discovery and analysis of such defective
conformational structures of POAG-associated
proteins may unlock breakthrough permanent
treatment avenues (Welsbie et al., 2013). With the
introduction of the iStent medical device, we believe
this device along with other similar stent-based devices
could provide long-term financial and clinical benefits.
The iStent in particular is promising as it bypasses the
genetic aspects of POAG and intervenes at the physical
level (direct insertion into the eye) with little to no
follow-ups (Resende et al., 2016).
A comprehensive understanding of POAG’s
unique genetic characteristics, history, molecular
mechanisms, and current research may provide key
insight to a cure for IOP-induced retinal ganglion cell
damage. Furthermore, because POAG remains so
prevalent in the United States, a complete
understanding of its history and etiology is crucial for
the development of long-term, financially viable,
treatment avenues.
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Appendix A: Figure 1. Anatomy of a healthy eye

Note. In this figure, the normal cycle of aqueous humor throughout the eye is depicted. Starting from the ciliary
processes and ending at Schlemm’s canal (black arrows). From “Schematic Diagram of the Aqueous Humor
Cycle” by Artur Llobet, Xavier Gaull, and Arcadi Gual licensed under CC BY 2.0.
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Appendix B: Figure 2. Development of Glaucoma

Note. This figure compares the flow of aqueous humor in a normal eye versus in an eye that develops Glaucoma
due to blockage of the trabecular meshwork tissue and subsequent increase of IOP. From “Development of
Glaucoma” by Alila Medical Media licensed under CC BY 2.0.
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Appendix C: Figure 3. POAG mechanism associated with the MYOC gene hotspot

Note. Figure 3.1. Increasing IOP results in radial & posterior distorting forces within the eye. Increased pressure
induces apoptosis/damage retinal ganglion cells & distort vision. Figure 3.2. The iris lies closer to the lens,
exhibiting the characteristic, “open-angle” between the iris & cornea (left). The presence of a “closed-angle”,
indicates the ciliary body & iris’ proximity to the cornea (right). In both diagrams, the trabecular meshwork is
non-functioning or damaged in Glaucoma, preventing the efficient drainage of aqueous humor. Figure 3.3.
Illustration of a point mutation on Exon 3-MYOC (gene implicated in POAG), resulting in a proline to a leucine
missense mutation. The mutant Myocilin (protein) product may potentially exhibit defects in one or several key
domains.
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Appendix D: Figure 4. Illustration of iStent function

Note. Left panel: Dysfunctional trabecular meshwork causes a build-up of aqueous humor. Right panel:
Installation of the iStent allows aqueous humor to properly drain; decreasing IOP.
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Appendix E: Figure 5. iStent anatomy

Note. The iStent anatomy allows for short & permanent procedures. Beginning with insertion using a needlepoint
self-trephining tip, retention arches secure the device in position, and allows aqueous humor to freely drain
through the trabecular meshwork (right). From “iStent Anatomy” by The Eye Institute licensed under CC BY 2.0.
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Appendix F: Figure 6. iStent(s) in the trabecular meshwork

Note. Left panel: Image of direct ophthalmoscopy of the eye. Right panel: iStent(s) are installed within the
trabecular meshwork which appears like white circles between the upper translucent layer (cornea) and lower
beige layer (iris, ciliary body). From “Direct Gonioscopy and 2 Inserted iStents Under Gonioscopy” by Journal
of Ophthalmology licensed under CC BY 2.0.
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